Literature DB >> 15234308

Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma.

Stefan Bleich1, Johannes Roedl, Nicolas Von Ahsen, Ursula Schlötzer-Schrehardt, Udo Reulbach, Georg Beck, Friedrich E Kruse, Gottfried O H Naumann, Johannes Kornhuber, Anselm G M Jünemann.   

Abstract

PURPOSE: To determine total homocysteine levels in aqueous humor of pseudoexfoliation open-angle glaucoma patients.
DESIGN: Case-control study.
METHODS: Total homocysteine levels were measured by enzyme-linked immunosorbent assay in aqueous humor and plasma of 29 patients with pseudoexfoliation glaucoma and 31 control patients with cataract. Patients with factors affecting homocysteine levels were excluded.
RESULTS: We observed significantly elevated (twofold) homocysteine levels in the aqueous humor of the glaucoma patients (Z = -5.11, P <.0001). Additionally, the calculated ratio (plasma:aqueous humor) was significantly lower in these patients (Z = -3.57, P <.001), and aqueous homocysteine was significantly correlated with their respective elevated plasma levels (r =.42, P =.02).
CONCLUSIONS: Because homocysteine induces vascular injury and alterations of extracellular matrix, high aqueous homocysteine may trigger the abnormal matrix accumulation characteristic. It may reflect the proposed impairment of the blood-aqueous barrier of pseudoexfoliation open-angle glaucoma and be involved in its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234308     DOI: 10.1016/j.ajo.2004.02.027

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  29 in total

Review 1.  [PEX syndrome. Clinical diagnosis and systemic manifestations].

Authors:  E Scharfenberg; U Schlötzer-Schrehardt
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

2.  Homocysteine levels in aqueous humor and plasma of patients with primary open-angle glaucoma.

Authors:  J B Roedl; S Bleich; U Reulbach; N von Ahsen; U Schlötzer-Schrehardt; R Rejdak; G O H Naumann; F E Kruse; J Kornhuber; A G M Jünemann
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

Review 3.  [Diagnosis and therapy of pseudoexfoliation glaucoma].

Authors:  A G M Jünemann
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

4.  High-sensitivity C-reactive Protein and Tumor Necrosis Factor Alpha in Pseudoexfoliation Syndrome.

Authors:  Rana Sorkhabi; Amir Ghorbanihaghjo; Mohamadhossein Ahoor; Mehriar Nahaei; Nadereh Rashtchizadeh
Journal:  Oman Med J       Date:  2013-01

5.  Directed therapy for exfoliation syndrome.

Authors:  Allison Angelilli; Robert Ritch
Journal:  Open Ophthalmol J       Date:  2009-09-17

6.  Directed Therapy: An Approach to the Improved Treatment of Exfoliation syndrome.

Authors:  Allison Angelilli; Robert Ritch
Journal:  Middle East Afr J Ophthalmol       Date:  2009-01

7.  Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand.

Authors:  Ying Dun; Muthusamy Thangaraju; Puttur Prasad; Vadivel Ganapathy; Sylvia B Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

8.  Disruption of the blood-aqueous barrier and lens abnormalities in mice lacking lysyl oxidase-like 1 (LOXL1).

Authors:  Janey L Wiggs; Basil Pawlyk; Edward Connolly; Michael Adamian; Joan W Miller; Louis R Pasquale; Ramez I Haddadin; Cynthia L Grosskreutz; Douglas J Rhee; Tiansen Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-10       Impact factor: 4.799

Review 9.  Consideration for gene-environment interactions as novel determinants of exfoliation syndrome.

Authors:  Louis R Pasquale; Jae H Kang; Janey L Wiggs
Journal:  Int Ophthalmol Clin       Date:  2014

10.  MTHFR gene C677T and A1298C polymorphisms and homocysteine levels in primary open angle and primary closed angle glaucoma.

Authors:  Shazia Micheal; Raheel Qamar; Farah Akhtar; Muhammad Imran Khan; Wajid Ali Khan; Asifa Ahmed
Journal:  Mol Vis       Date:  2009-11-09       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.